Abstract 14707: Synergistic Cardiovascular Benefits of Combined GLP-1 Receptor Agonists and SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy in Patients with Type 2 Diabetes and HFpEF
Abstract
Background: Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular benefits in type 2 diabetes (T2D). While SGLT2i is a cornerstone therapy for heart failure with preserved ejection fraction (HFpEF), the incremental prognostic benefit of adding a GLP-1RA in this specific, high-risk population remains under-investigated. This real-world study evaluates whether combined dual therapy offers superior cardioprotective outcomes compared to SGLT2i alone in patients with T2D and HFpEF. Methods: Utilizing the TriNetX global federated research network, we identified adult patients diagnosed with T2D and HFpEF. Patients were stratified into two cohorts: combined GLP-1RA and SGLT2i therapy (Cohort 1) versus SGLT2i monotherapy (Cohort 2). Propensity score matching (PSM) at a 1:1 ratio balanced baseline demographics, comorbidities, and critical laboratory values (including eGFR, BMI, HbA1c, and LVEF). The primary endpoints analyzed were All-Cause Mortality (ACM), Major Adverse Cardiovascular Events (MACE), Heart Failure Exacerbation over a one-year follow-up period.Results: Following PSM, each cohort consisted of 21,048 well-matched patients. Baseline characteristics are summarized in Table 1. Dual therapy demonstrated profound superiority across evaluated cardiovascular and mortality endpoints. Compared to SGLT2i monotherapy, the GLP-1RA + SGLT2i combination yielded a 48.1% lower hazard for all-cause mortality (HR: 0.519, 95% CI: 0.479–0.562, p < 0.0001). Furthermore, combination therapy resulted in a 27.1% relative risk reduction in MACE (HR: 0.729, 95% CI: 0.698–0.762, p < 0.0001). The incidence of heart failure exacerbations was also lower in the dual therapy cohort (54.27%) compared to the monotherapy group (57.76%). Conclusion: In a large, propensity-matched cohort of patients with T2D and HFpEF, the addition of GLP-1RA to SGLT2i therapy was associated with significantly superior reductions in all-cause mortality, MACE, and heart failure exacerbations compared to SGLT2i monotherapy alone. These real-world data strongly support the early synergistic use of dual incretin and SGLT2 inhibition to improve survival and reduce acute decompensation in HFpEF.